Key Stats for Eli Lilly Stock
- YTD Price Change for Eli Lilly stock: 33%
- $LLY Share Price as of Nov. 21: $1,060
- 52-Week High: $1,066
- $LLY Stock Price Target: $1,012
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) stock made history on Friday, becoming the first healthcare company to reach a $1 trillion market capitalization.
The milestone puts Eli Lilly in exclusive company alongside tech giants like Apple, Microsoft, and Nvidia. It’s only the second non-technology company in the U.S. to hit the trillion-dollar mark after Warren Buffett’s Berkshire Hathaway.
The surge comes as investors reward Eli Lilly’s dominance in the red-hot GLP-1 drug market. The Indianapolis-based drugmaker has been crushing rival Novo Nordisk thanks to blockbuster sales of its weight loss injection Zepbound and diabetes treatment Mounjaro.
Both drugs use tirzepatide, a dual-acting molecule that targets two gut hormones (GLP-1 and GIP) instead of just one, like Novo’s semaglutide products.
In the company’s most recent quarter, Mounjaro generated $6.52 billion in revenue, up 109% from the previous year. Zepbound posted even more impressive growth, with $3.59 billion in sales, a 184% year-over-year increase.
Together, the two drugs accounted for over $10 billion of Eli Lilly’s quarterly revenue as the company reported total sales growth of 54%.
Eli Lilly is winning market share in the U.S. incretin market for the fifth straight quarter. The company now captures nearly 60% of all prescriptions in this massive and growing drug class.
Mounjaro has become the most widely prescribed incretin for type 2 diabetes patients in the U.S., while Zepbound exited the quarter with 71% share of new prescriptions in the branded obesity market.
The growth story extends far beyond U.S. borders, as Mounjaro has now launched in 55 countries and received a strong global reception.
What’s particularly striking is that approximately 75% of international Mounjaro revenue comes from patients with obesity paying out of pocket, demonstrating high clinical need and a willingness to pay despite limited insurance coverage.
LLY stock got another boost from the company’s pipeline progress.
- Eli Lilly announced positive results from multiple Phase III trials of orforglipron, its oral GLP-1 pill that could hit the market next year.
- The oral version would give patients a more convenient option than injections and is easier for the company to manufacture at scale.
- In head-to-head trials, orforglipron demonstrated superior efficacy compared with oral semaglutide for both blood sugar reduction and weight loss.
Management also raised full-year guidance, citing strong underlying performance. The company now expects 2025 revenue between $63 billion and $63.5 billion, up over $2 billion from prior guidance. Earnings per share guidance increased to a range of $23 to $23.70.
Beyond GLP-1s, Eli Lilly continues expanding its pipeline. The company received FDA approval for breast cancer treatment Inluriyo and EU approval for Alzheimer’s drug Kisunla.
Management announced plans to build two new U.S. manufacturing facilities and expand an existing facility in Puerto Rico to support future demand.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
What the Market Is Telling Us About LLY Stock
The market’s enthusiasm for LLY stock reflects confidence that Eli Lilly’s dominance in the obesity and diabetes markets is just beginning.
Analysts believe the weight loss drug market could be worth more than $150 billion by the early 2030s, and Eli Lilly appears positioned to capture the lion’s share.
Several factors support continued momentum. First, the company is literally just scratching the surface of global treatment.
Only about 8 million people in the U.S. are currently on incretins out of roughly 170 million who might benefit. Globally, that opportunity extends to hundreds of millions or even billions of patients.
Second, Eli Lilly’s dual-mechanism tirzepatide continues to show superior efficacy compared with single-acting GLP-1s in clinical trials. This clinical differentiation is translating to market share gains and pricing power.
Third, the upcoming launch of orforglipron could be transformational, offering a simple once-daily pill with no food or water restrictions that’s easier to manufacture at scale.
Competition is intensifying as Pfizer recently won a $10 billion bidding war for obesity drugmaker Metsera, and Novo Nordisk remains a formidable rival despite recent struggles.
But LLY stock investors appear confident that Eli Lilly’s innovation engine, manufacturing scale, and execution track record will maintain its leadership position in what may be the most lucrative pharmaceutical market ever created.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Eli Lilly Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
